Literature DB >> 33529052

A pilot study on lung cancer detection based on regional metabolic activity distribution in digital low-dose 18F-FDG PET.

Michael Messerli1,2,3, Urs J Muehlematter1,3,4, Saskia Fassbind1,3, Daniel Franzen3,5, Daniela A Ferraro1, Martin W Huellner1,3, Valerie Treyer1,3, Alessandra Curioni-Fontecedro3,6, Irene A Burger1,3,7.   

Abstract

OBJECTIVES: To investigate the potential of automatic lung cancer detection on submillisievert dose 18F-fludeoxyglucose (18F-FDG) scans using different positron emission tomography (PET) parameters, as a primary step towards a potential new indication for 18F-FDG PET in lung cancer screening.
METHODS: We performed a retrospective cohort analysis with 83 patients referred for 18F-FDG PET/CT, including of 34 patients with histology-proven lung cancer and 49 patients without lung disease. Aside clinical standard PET images (PET100%) two additional low-dose PET reconstructions were generated, using only 15 s and 5 s of the 150 s list mode raw data of the full-dose PET, corresponding to 10% and 3.3% of the original 18F-FDG activity. The lungs were subdivided into three segments on each side, and each segment was classified as normal or containing cancer. The following standardized uptake values (SUVs) were extracted from PET per lung segment: SUVmean, SUVhot5, SUVmedian, SUVstd and SUVtotal. A multivariate linear regression model was used and cross-validated. The accuracy for lung cancer detection was tested with receiver operating characteristics analysis and T-statistics was used to calculate the weight of each parameter.
RESULTS: The T-statistics showed that SUVstd was the most important discriminative factor for lung cancer detection. The multivariate model achieved an area under the curve of 0.97 for full-dose PET, 0.85 for PET10% with PET3.3% reconstructions resulting in a still high sensitivity the PET10% reconstruction of 80%.
CONCLUSION: This pilot study indicates that segment-based, quantitative PET parameters of low-dose PET reconstructions could be used to automatically detect lung cancer with high sensitivity. ADVANCES IN KNOWLEDGE: Automated assessment of PET parameters in low-dose PET may aid for an early detection of lung cancer.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33529052      PMCID: PMC8011269          DOI: 10.1259/bjr.20200244

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  16 in total

1.  Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT.

Authors:  Jared A Christensen; Mark A Nathan; Brian P Mullan; Thomas E Hartman; Stephen J Swensen; Val J Lowe
Journal:  AJR Am J Roentgenol       Date:  2006-11       Impact factor: 3.959

Review 2.  Effective doses in radiology and diagnostic nuclear medicine: a catalog.

Authors:  Fred A Mettler; Walter Huda; Terry T Yoshizumi; Mahadevappa Mahesh
Journal:  Radiology       Date:  2008-07       Impact factor: 11.105

3.  Quantitative Accuracy and Lesion Detectability of Low-Dose 18F-FDG PET for Lung Cancer Screening.

Authors:  Joshua D Schaefferkoetter; Jianhua Yan; Therese Sjöholm; David W Townsend; Maurizio Conti; John Kit Chung Tam; Ross A Soo; Ivan Tham
Journal:  J Nucl Med       Date:  2016-09-29       Impact factor: 10.057

4.  Probability of cancer in pulmonary nodules detected on first screening CT.

Authors:  Annette McWilliams; Martin C Tammemagi; John R Mayo; Heidi Roberts; Geoffrey Liu; Kam Soghrati; Kazuhiro Yasufuku; Simon Martel; Francis Laberge; Michel Gingras; Sukhinder Atkar-Khattra; Christine D Berg; Ken Evans; Richard Finley; John Yee; John English; Paola Nasute; John Goffin; Serge Puksa; Lori Stewart; Scott Tsai; Michael R Johnston; Daria Manos; Garth Nicholas; Glenwood D Goss; Jean M Seely; Kayvan Amjadi; Alain Tremblay; Paul Burrowes; Paul MacEachern; Rick Bhatia; Ming-Sound Tsao; Stephen Lam
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

5.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

6.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

7.  Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.

Authors:  Harry J de Koning; Carlijn M van der Aalst; Pim A de Jong; Ernst T Scholten; Kristiaan Nackaerts; Marjolein A Heuvelmans; Jan-Willem J Lammers; Carla Weenink; Uraujh Yousaf-Khan; Nanda Horeweg; Susan van 't Westeinde; Mathias Prokop; Willem P Mali; Firdaus A A Mohamed Hoesein; Peter M A van Ooijen; Joachim G J V Aerts; Michael A den Bakker; Erik Thunnissen; Johny Verschakelen; Rozemarijn Vliegenthart; Joan E Walter; Kevin Ten Haaf; Harry J M Groen; Matthijs Oudkerk
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 91.245

8.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

Review 9.  Dosage optimization in positron emission tomography: state-of-the-art methods and future prospects.

Authors:  Nicolas A Karakatsanis; Eleni Fokou; Charalampos Tsoumpas
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-10-12

10.  Ultralow dose CT for pulmonary nodule detection with chest x-ray equivalent dose - a prospective intra-individual comparative study.

Authors:  Michael Messerli; Thomas Kluckert; Meinhard Knitel; Stephan Wälti; Lotus Desbiolles; Fabian Rengier; René Warschkow; Ralf W Bauer; Hatem Alkadhi; Sebastian Leschka; Simon Wildermuth
Journal:  Eur Radiol       Date:  2017-01-16       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.